Related Experiment Video
Updated: Jun 9, 2026

Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
Gut mucosa alterations after kidney transplantation: a cross sectional study
Rashmi Joshi1, Carmine Secondulfo2, Alessandro Caputo3
1Department of Translational Medical Sciences, University of Campania, Via Pansini, 5, 80131, Naples, Italy.
Background:
Kidney transplant recipients (KTRs) rely on immunosuppressants like mycophenolate to prevent organ rejection. However, mycophenolate often causes intestinal symptoms and inflammation in various organs, including the skin and the colon. While KTRs have an increased risk for skin cancer, the risk of colorectal cancer is not increased. Elucidating the histological alterations in the colon of KTRs and comparing these changes with known skin alterations would help understand how immunosuppressants influence cancer development and progression.
Methods:
Whole slide images from gut biopsies (Non-transplanted subjects n = 35, KTRs n = 49) were analyzed using the ImageJ and R programming environment. A total of 22,035 epithelial cells, 38,870 interstitial cells, 3465 epithelial cell mitoses, and 7477 endothelial cells, each characterized by multiple microscopy parameters, from a total of 1788 glands were analyzed. The large database was subsequently analyzed to verify the changes of inflammatory milieu in KTRs and in cancer.
Results:
KTRs without colon-cancer showed a significantly higher density of interstitial cells in the colon compared to non-transplanted patients. Moreover, the increase in interstitial cell number was accompanied by subtle modifications in the architecture of the colon glands, without altering the epithelial cell density. We could not identify significant structural modifications in cancer samples between KTRs and non-transplanted patients.
Conclusions:
Our findings demonstrate an increased number of resident interstitial cells in the colon of KTRs, as in other patients treated with mycophenolate. These changes are associated with subtle alterations in the architecture of colon glands.
Insights
Kidney transplant recipients on mycophenolate show increased interstitial cells in the colon, leading to subtle gland architectural changes. This study clarifies immunosuppressant effects on the gut, distinct from cancer risk.
Area of Science:
- Gastroenterology
- Transplant Medicine
- Oncology
Background:
- Kidney transplant recipients (KTRs) use immunosuppressants like mycophenolate, which can cause intestinal issues and inflammation.
- While KTRs have higher skin cancer risk, colorectal cancer risk is not elevated.
- Understanding colon histological changes in KTRs may reveal immunosuppressant impacts on cancer development.
Purpose of the Study:
- To investigate histological alterations in the colon of KTRs.
- To compare colon changes in KTRs with known skin alterations.
- To understand how immunosuppressants influence cancer development and progression.
Main Methods:
- Analysis of whole slide images from gut biopsies of KTRs (n=49) and non-transplanted subjects (n=35).
- Utilized ImageJ and R programming for quantitative analysis of epithelial, interstitial, mitotic, and endothelial cells.
- Examined 1788 glands to assess inflammatory milieu changes in KTRs and cancer patients.
Main Results:
- KTRs without colon cancer exhibited significantly higher interstitial cell density compared to controls.
- Increased interstitial cells correlated with subtle colon gland architectural modifications, not epithelial cell density changes.
- No significant structural differences in cancer samples were found between KTRs and non-transplanted patients.
Conclusions:
- KTRs treated with mycophenolate display an increased number of resident interstitial cells in the colon.
- These cellular changes are linked to subtle alterations in colon gland architecture.
- Findings contribute to understanding immunosuppressant-induced colonic changes.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management

